The burden of multiple sclerosis in Japan
- PMID: 28849983
- DOI: 10.1080/13696998.2017.1373653
The burden of multiple sclerosis in Japan
Abstract
Aims: Multiple sclerosis (MS) is a disabling autoimmune disease affecting the central nervous system. Few studies have examined the effect of MS on patient outcomes in Japan. The study aim was to quantify MS burden in Japan by comparing MS respondents to matched controls on patient outcomes.
Materials and methods: Data from seven administrations of the nationally representative Japan National Health and Wellness Survey (2009-2014 and 2016) were used (n = 181,423). Respondents self-reporting MS diagnosis were compared with respondents not reporting MS. Matched controls were selected using propensity scores. Respondents with MS and matched controls were compared on health-related quality-of-life (HRQoL), work productivity and activity impairment, healthcare resource utilization, and costs. Comparisons were made using Chi-square tests or one-way ANOVAs.
Results: A total of 96 respondents with MS and 480 matched controls were included in the analyses. MS respondents reported worse mental (44.35 vs 47.51, p < .05), physical (33.11 vs 49.04, p < .001), and role (37.78 vs 47.11, p < .001) component summary scores (minimally important difference is 3.0). Additionally, MS respondents reported decrements on every health profile sub-scale (p < .001) and 5-Level EuroQoL-5 Dimensions outcome (p < .01). MS respondents also reported more healthcare provider visits (13.78 vs 6.13) and hospitalizations (3.02 vs 0.70; both, p < .001), leading to higher direct costs. For work productivity and activity impairment, MS respondents reported more absenteeism (17.50% vs 5.57%), presenteeism (38.11% vs 21.62%), overall work impairment (46.68% vs 25.27%), and activity impairment (46.88% vs 24.90%, all, p < .001), leading to higher indirect costs.
Limitations: Japan NHWS data are cross-sectional, and causal relationships cannot be established. Due to the self-reported nature of the data, responses could not be independently verified.
Conclusions: Results suggest MS in Japan is associated with poorer HRQoL and greater work and activity impairment, healthcare resource use, and costs. Improved MS management could benefit both patients and society.
Keywords: Japan; Multiple sclerosis; activity impairment; costs; patient reported outcomes; quality-of-life; resource use; work productivity.
Similar articles
-
Health-related quality-of-life, work productivity, and economic burden among patients with Parkinson's disease in Japan.J Med Econ. 2018 Dec;21(12):1206-1212. doi: 10.1080/13696998.2018.1522638. Epub 2018 Oct 1. J Med Econ. 2018. PMID: 30200795
-
Burden of relapsing-remitting multiple sclerosis on workers in the US: a cross-sectional analysis of survey data.BMC Neurol. 2019 Oct 28;19(1):258. doi: 10.1186/s12883-019-1495-z. BMC Neurol. 2019. PMID: 31660897 Free PMC article.
-
Assessment of economic burden of fatigue in adults with multiple sclerosis: An analysis of US National Health and Wellness Survey data.Mult Scler Relat Disord. 2022 Sep;65:103971. doi: 10.1016/j.msard.2022.103971. Epub 2022 Jun 14. Mult Scler Relat Disord. 2022. PMID: 35843012
-
[The Multiple Sclerosis Health Resource Utilization Survey].Fortschr Neurol Psychiatr. 2022 Jan;90(1-02):42-48. doi: 10.1055/a-1471-3636. Epub 2021 May 18. Fortschr Neurol Psychiatr. 2022. PMID: 34005824 Review. German.
-
The economics of multiple sclerosis. Distribution of costs and relationship to disease severity.Pharmacoeconomics. 1999 Mar;15(3):229-40. doi: 10.2165/00019053-199915030-00003. Pharmacoeconomics. 1999. PMID: 10537431 Review.
Cited by
-
Health-related outcomes, health care resource utilization, and costs of multiple sclerosis in Japan compared with US and five EU countries.Clinicoecon Outcomes Res. 2019 Jan 7;11:61-71. doi: 10.2147/CEOR.S179903. eCollection 2019. Clinicoecon Outcomes Res. 2019. PMID: 30662276 Free PMC article.
-
New Insights into Risk Genes and Their Candidates in Multiple Sclerosis.Neurol Int. 2022 Dec 29;15(1):24-39. doi: 10.3390/neurolint15010003. Neurol Int. 2022. PMID: 36648967 Free PMC article. Review.
-
People Diagnosed with Myasthenia Gravis have Lower health-related quality of life and Need More Medical and Caregiver Help in Comparison to the General Population: Analysis of Two Observational Studies.Adv Ther. 2023 Oct;40(10):4377-4394. doi: 10.1007/s12325-023-02604-z. Epub 2023 Jul 25. Adv Ther. 2023. PMID: 37490259 Free PMC article.
-
Health-Related Quality of Life in Patients With Different Diseases Measured With the EQ-5D-5L: A Systematic Review.Front Public Health. 2021 Jun 29;9:675523. doi: 10.3389/fpubh.2021.675523. eCollection 2021. Front Public Health. 2021. PMID: 34268287 Free PMC article.
-
Glatiramer Acetate Immunomodulation: Evidence of Neuroprotection and Cognitive Preservation.Cells. 2022 May 7;11(9):1578. doi: 10.3390/cells11091578. Cells. 2022. PMID: 35563884 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical